- Home
- AMBO vs EDSA Comparison
AMBO vs EDSA Comparison
Compare AMBO & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- EDSA
- Stock Information
- Founded
- AMBO 2000
- EDSA 2015
- Country
- AMBO United States
- EDSA Canada
- Employees
- AMBO N/A
- EDSA N/A
- Industry
- AMBO Other Consumer Services
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- EDSA Health Care
- Exchange
- AMBO Nasdaq
- EDSA Nasdaq
- Market Cap
- AMBO 6.0M
- EDSA 6.2M
- IPO Year
- AMBO 2010
- EDSA N/A
- Fundamental
- Price
- AMBO $2.18
- EDSA $1.90
- Analyst Decision
- AMBO
- EDSA Strong Buy
- Analyst Count
- AMBO 0
- EDSA 1
- Target Price
- AMBO N/A
- EDSA $21.00
- AVG Volume (30 Days)
- AMBO 528.7K
- EDSA 17.3K
- Earning Date
- AMBO 12-30-2024
- EDSA 02-07-2025
- Dividend Yield
- AMBO N/A
- EDSA N/A
- EPS Growth
- AMBO N/A
- EDSA N/A
- EPS
- AMBO N/A
- EDSA N/A
- Revenue
- AMBO $7,839,000.00
- EDSA N/A
- Revenue This Year
- AMBO N/A
- EDSA N/A
- Revenue Next Year
- AMBO N/A
- EDSA N/A
- P/E Ratio
- AMBO N/A
- EDSA N/A
- Revenue Growth
- AMBO N/A
- EDSA N/A
- 52 Week Low
- AMBO $1.00
- EDSA $1.55
- 52 Week High
- AMBO $6.30
- EDSA $5.99
- Technical
- Relative Strength Index (RSI)
- AMBO 48.94
- EDSA 44.32
- Support Level
- AMBO $1.77
- EDSA $1.65
- Resistance Level
- AMBO $2.29
- EDSA $1.94
- Average True Range (ATR)
- AMBO 0.36
- EDSA 0.14
- MACD
- AMBO -0.06
- EDSA 0.02
- Stochastic Oscillator
- AMBO 26.81
- EDSA 45.45
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.